Invitae’s Personalized Cancer Monitoring Assay Gets First Commercial Coverage
Invitae’s personalized cancer monitoring assay for MRD obtained its first commercial coverage in solid tumors by Blue Shield of California.
Read MorePosted by Andy Lundin | Mar 6, 2023 | Cancer |
Invitae’s personalized cancer monitoring assay for MRD obtained its first commercial coverage in solid tumors by Blue Shield of California.
Read MorePosted by Andy Lundin | Mar 3, 2023 | Lab Automation, Molecular Diagnostics |
Automated NGS platforms can help determine if a patient is fit for a targeted therapy, enabling more effective precision medicine.
Read MorePosted by Andy Lundin | Mar 2, 2023 | Cancer |
Investigators at Children’s Hospital Los Angeles investigators have developed a liquid biopsy for pediatric solid tumors.
Read MorePosted by Andy Lundin | Mar 1, 2023 | Prenatal Testing |
Devyser Compact is a rapid genetic test for prenatal chromosome testing and is approved under the new more comprehensive regulation.
Read MorePosted by Andy Lundin | Feb 24, 2023 | Womens Health |
Women who developed mood and anxiety disorders related to pregnancy and childbirth had altered proteins circulating in their bloodstream.
Read More